Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

Irish Abstracts Presented at ASCO 2004

• Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3D radiation for non small cell lung carcinoma.

• Phase IU randomised tri& of doxorubicin (A) and docetaxel & (D) versus A and Cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer.

• Effect of tandem highdose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-L

• Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatn) (TCH) in women with HER2+ advanced breast cancer (ABC).

• Are inter-country variations in the use of expensive oncology products (EOP) partly responsible for differing cancer treatment outcomes?

• Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) – final results of a British Thoracic Oncology Group (BTOG) trial.

• Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC).

• Phase I clinical and pharmacokinetic study of the farnesyl transferase inhibitor BMS-214662 administered intravenously for five consecutive days in patients with advanced malignancies.